Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.108 (
lactase
)
2,133
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have described the methods used for studying the biosynthesis and the post-translational processing of sucrase-isomaltase (SI),
lactase-phlorizin hydrolase
(
LPH
) and maltase-glucoamylase (MGA) in human small intestinal mucosa. Our results are discussed in the context of findings by other researchers. A surprising finding coming out of all these studies is that SI,
LPH
and MGA are structurally quite different. SI and
LPH
are both synthesized as large molecular weight precursors which are proteolytically processed to the mature enzymes. In the case of SI, this processing occurs after insertion of the precursor into the brush border membrane and is catalysed by pancreatic proteases; the mature form consists of the two subunits sucrase and isomaltase, the latter containing an
N-terminal peptide
anchor. Proteolytic processing of the
LPH
-precursor occurs intracellularly, yielding a mature enzyme in the form of a two active site polypeptide which is anchored via a
C-terminal peptide
. The role of the large cleaved propolypeptide of
LPH
is not yet known. MGA is the largest of the three disaccharidases, having a molecular weight of greater than 300 kDa. No proteolytic processing seems to be taking place during biogenesis of MGA in human mucosa, and the mode of attachment to the membrane is unknown at present. The application of the methods described to the investigation of congenital sucrase-isomaltase deficiency (CSID) and
lactase
restriction in adults is presented and differences between CSID and
LPH
restriction are discussed.
...
PMID:Molecular aspects of disaccharidase deficiencies. 211 33